Rigel Pharmaceuticals Inc to Discuss FORWARD Study Results Transcript
Greetings, and welcome to the Rigel Pharmaceuticals conference call to discuss FORWARD study results. (Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn the call over to Dolly Vance, Executive Vice President, Corporate Affairs and General Counsel. Thank you. You may begin.
Welcome, and thank you for joining us today to discuss topline results from the FORWARD pivotal Phase III clinical trial of fostamatinib in patients with warm autoimmune hemolytic anemia, who have failed at least one prior treatment. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties and may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent annual report on Form 10-K
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |